Friday, September 18, 2015 | 8:30 AM - 4:30 PM
Speakers: George S. Bloom (University of Virginia), Peter Davies (Feinstein Institute for Medical Research), Marc I. Diamond (University of Texas, Southwestern Medical Center), Michael Hutton (Eli Lilly and Company), Khalid Iqbal (New York State Institute for Basic Research in Developmental Disabilities), Hartmuth C. Kolb (Johnson & Johnson, Janssen R&D), Nicole Leclerc (Université de Montréal), Richard Ransohoff (Biogen)
Speakers at this symposium will address novel tau-centered mechanisms of neurodegeneration and new therapeutic approaches for many devastating neurological disorders.
Thursday, June 11, 2015 | 8:45 AM - 5:15 PM
Keynote Speaker: Jane A. Driver (Brigham and Women's Hospital)
Speakers: Kurt Brunden (University of Pennsylvania), Stuart Calderwood (Harvard Medical School), Gary Landreth (Case Western Reserve University), Tamara Maes, PhD (Oryzon Genomics S.A.), David M. Roy (Memorial Sloan Kettering Cancer Center), Stephen Strittmatter (Yale University School of Medicine), Li Huei Tsai (Massachusetts Institute of Technology), Raymond Scott Turner (Georgetown University), Claes Wahlestedt (University of Miami Miller School of Medicine), Hui Zheng (Baylor College of Medicine)
Does having cancer decrease your risk of developing neurodegenerative diseases? Why do many cancer drug targets overlap with targets for neurodegenerative diseases? This meeting will address these questions to help advance therapeutic development.
Monday, April 27, 2015 | 8:30 AM - 4:45 PM
Speakers: Erwan Bezard (University of Bordeaux), Patrik Brundin (Van Andel Institute), Marie-Francoise Chesselet (UCLA), Diane G. Cook (Parkinson's Disease Foundation), Maurizio Facheris (The Michael J. Fox Foundation for Parkinson's Research), Horacio Kaufmann (NYU Langone Medical Center), Olivier Rascol (University of Toulouse), Anna Sauerbier (NPF International Centre of Excellence, Kings College London), Daniel Weintraub (University of Pennsylvania)
This symposium will review clinical tools for the diagnosis and treatment of non-motor symptoms of Parkinson's disease, discuss the disease mechanisms, and address preclinical models for the development of new therapeutics.
March 26 - 27, 2015
Keynote Speakers: Miia Kivipelto (Karolinska Institutet), Irwin H. Rosenberg (Tufts University), A. David Smith (University of Oxford)
Speakers: Cédric Annweiler (Angers University Hospital), Stephen Cunnane (Université de Sherbrooke), Agnes Flöel (Charité - University Medicine Berlin), Gary E. Gibson (Weill Cornell Medical College, Burke Medical Research Institute), Richard S. Isaacson (Weill Cornell Medical College, New York-Presbyterian Hospital), Heather H. Keller (University of Waterloo), Max Lugavere (Independent Documentary Filmmaker), Joshua W. Miller (Rutgers, The State University of New Jersey), Martha Clare Morris (Rush University), Suzana Petanceska (National Institute on Aging), Helga Refsum (University of Oslo, Norway), Kirsten Tillisch (David Geffen School of Medicine at UCLA), Katherine L. Tucker (University of Massachusetts, Lowell), Natalia Wagemans (Nestlé Nutrition Institute)
This conference will discuss issues of epidemiological perspectives and the role of nutrition in dementia prevention and management.
Tuesday, February 24, 2015 | 8:30 AM - 4:30 PM
Speakers: Chad Cowan (Harvard University), James Inglese (National Center for Advancing Translational Sciences, NIH), J. Keith Joung (Massachusetts General Hospital), Randall Platt (Massachusetts Institute of Technology), Yi Yang (Novartis Institutes for Biomedical Research), Lei (Stanley) Qi (University of California San Francisco)
The emergence of genome editing technologies such as TALEN and CRISPR/Cas9 are revolutionizing our ability to rapidly engineer mammalian systems. This symposium explores the frontiers of genome editing and potential to aid therapeutic development.
Organizers: Nathalie Breysse (Lundbeck Research USA), Elena Dale (Lundbeck Research USA), and Sonya Dougal (The New York Academy of Sciences)
Non-motor symptoms are common but often overlooked in Parkinson's disease. This eBriefing examines new approaches to studying disease mechanisms, which could lead to a better understanding of pathogenesis and to the development of new therapies.
Keynote Speakers: Miia Kivipelto (Karolinska Institute, Sweden), Irwin H. Rosenberg (Tufts University), and A. David Smith (University of Oxford, UK)
This eBriefing discusses epidemiological evidence for the role of diet in cognitive function and looks at nutritional and lifestyle strategies to delay or prevent dementia.
Edited by Matthew E. Fink
(Weill Cornell Medical College), Jack D. Barchas
(Weill Cornell Medical College), and Javaid I. Sheikh
(Weill Cornell Medical College in Qatar)
Discussions of the latest translational research, advanced brain imaging, & novel diagnostics
Edited by Annals of the New York Academy of Sciences
This Annals volume discusses progress in neuroscience that translates to new treatments for psychiatric illness, with a focus on progress in developing quantitative endpoints to measure disease progression and response to therapy in depression and schizophrenia.
A recent conference held at the Academy asked a downright outrageous question: Can dementia be prevented by making changes to your diet? In this podcast we look at what the answers might be.
In the second of a two-part series, experts look at the links between health and nutrition. They examine everything from how nutrition impacts hospital stays, to cancer and aging, to developing food science innovations, and improving diet.
In this first of a two-part series, experts from various sectors explore the available options to reduce "hidden hunger"—micronutrient deficiencies in a population.
February 23, 2010
Researchers met to discuss advances in basic and translational research on metabotropic glutamate receptors, which are promising targets in drug discovery for CNS diseases and other illnesses.
October 27, 2009
What is the connection between dysregulated neuronal insulin signaling and Alzheimer's disease? In a recent Academy webinar, some researchers argued that the neurodegenerative disease should be considered a type of diabetes.